UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 6-K



REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

Date: July 28, 2023

Commission File Number: 001-41338



IperionX Limited
(Translation of registrant’s name into English)



129 W Trade Street, Suite 1405
Charlotte, North Carolina
(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐



Explanatory Note:

The Registrant is furnishing this Report on Form 6-K to provide its unaudited interim financial report for the six months ended December 31, 2022 in XBRL format.

EXHIBIT INDEX

The following exhibits are filed as part of this Form 6-K:

Exhibit
 
Description
   
 
Interim Financial Report for the Six Months Ended December 31, 2022
101.INS
 
Inline XBRL Instance Document.
101.SCH
 
Inline XBRL Taxonomy Extension Schema Document.
101.CAL
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
 
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
 
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
IPERIONX LIMITED
 
(registrant)
   
Date: July 28, 2023
By:
/s/ Gregory Swan
 
Name:
Gregory Swan
 
Title:
Chief Financial Officer




Exhibit 99.1

graphic
 
IPERIONX LIMITED
ABN 84 618 935 372
 
Interim Financial Report
 
for the Six Months Ended
 
December 31, 2022

North Carolina
Tennessee
Virginia
Utah
129 W Trade Street, Suite 1405
Charlotte, NC 28202
279 West Main Street
Camden, TN 38320
1030 Confroy Drive
South Boston, VA 24592
1782 W 2300 S
West Valley City, UT 84119
 

Corporate Directory
graphic
DIRECTORS

Mr. Todd Hannigan – Executive Chairman
Mr. Anastasios Arima – CEO & Managing Director
Ms. Lorraine Martin – Independent Non-Executive Director
Mr. Vaughn Taylor – Independent Non-Executive Director
Ms. Melissa Waller – Independent Non-Executive Director
Ms. Beverly Wyse – Independent Non-Executive Director

COMPANY SECRETARY

Mr Gregory Swan

OFFICES

North Carolina
129 W Trade Street, Suite 1405
Charlotte, NC 28202, UNITED STATES

Tennessee
279 West Main Street
Camden, TN 38320, UNITED STATES

Virginia
1030 Confroy Drive
South Boston, VA 24592, UNITED STATES

Utah
1782 W 2300 S
West Valley City, UT 84119, UNITED STATES

Registered office
28 The Esplanade, Level 9
Perth, WA 6000, AUSTRALIA
WEBSITE

www.iperionx.com

STOCK EXCHANGE LISTINGS

Nasdaq Capital Market:
American depositary shares (NASDAQ: IPX)

Australian Securities Exchange:
Fully paid ordinary shares (ASX: IPX)

SHARE REGISTRY

Automic Pty Ltd
T: 1300 288 664 (within Australia)
T: +61 2 9698 5414 (international)

LAWYERS

United States
Gibson, Dunn & Crutcher
Johnston Allison & Hord

Australia
Thomson Geer Lawyers

AUDITOR

PricewaterhouseCoopers

CONTENTS
 
 
Page
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
1
Condensed Consolidated Statement of Financial Position
2
Condensed Consolidated Statement of Changes in Equity
3
Condensed Consolidated Statement of Cash Flows
4
Notes to the Condensed Consolidated Financial Statements
5
   
 
IperionX Limited Financial Report for the Six Months Ended December 31, 2022
i

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
FOR THE SIX MONTHS ENDED DECEMBER 31, 2022
graphic

 Note  
Six Months Ended
December 31, 2022
US$
   
Six Months Ended
December 31, 2021
US$
 
             
Continuing operations
           
Exploration and evaluation expenses
   
(1,517,474
)
   
(2,734,807
)
Research and development costs
   
(2,099,309
)
   
(696,715
)
Corporate and administrative expenses
   
(2,161,671
)
   
(998,378
)
Business development expenses
   
(1,333,073
)
   
(1,501,724
)
Share-based payment expense
   
(1,566,231
)
   
(4,764,135
)
Finance income
   
198,282
     
157,435
 
Finance costs
   
(30,717
)
   
(23,831
)
Other income and expenses
   
(243,884
)
   
-
 
Loss before income tax
   
(8,754,077
)
   
(10,562,155
)
Income tax expense
   
-
     
-
 
Loss for the period
   
(8,754,077
)
   
(10,562,155
)
Loss attributable to members of IperionX Limited
   
(8,754,077
)
   
(10,562,155
)
                 
Other comprehensive income
               
Items that may be reclassified subsequently to profit or loss:
               
Exchange differences arising on translation of foreign operations
   
(102,645
)
   
(232,068
)
Other comprehensive loss for the period, net of tax
   
(102,645
)
   
(232,068
)
Total comprehensive loss for the period
   
(8,856,722
)
   
(10,794,223
)
Total comprehensive loss attributable to members of IperionX Limited
   
(8,856,722
)
   
(10,794,223
)
                 
Loss per share
               
Basic and diluted loss per share (US$ per share)
   
(0.06
)
   
(0.08
)

The above Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

IperionX Limited Financial Report for the Six Months Ended December 31, 2022
1

Condensed Consolidated Statement of Financial Position
AS AT DECEMBER 31, 2022
graphic

   
Note
   
December 31, 2022
US$
   
June 30, 2022
US$
 
                   
ASSETS
                 
Current Assets
                 
Cash and cash equivalents
         
11,438,526
     
5,672,551
 
Trade and other receivables
         
84,477
     
22,540
 
Prepayments
         
255,149
     
144,183
 
Total Current Assets
         
11,778,152
     
5,839,274
 
                       
Non-Current Assets
                     
Exploration and evaluation assets
   
4
     
2,849,429
     
2,431,229
 
Property, plant and equipment
   
5
     
3,369,099
     
1,387,986
 
Financial assets
           
-
     
250,000
 
Total Non-Current Assets
           
6,218,528
     
4,069,215
 
TOTAL ASSETS
           
17,996,680
     
9,908,489
 
                         
LIABILITIES
                       
Current Liabilities
                       
Trade and other payables
   
6
     
1,468,271
     
1,899,348
 
Loans and borrowings
   
7
     
363,860
     
134,247
 
Provisions
           
-
     
46,392
 
Total Current Liabilities
           
1,832,131
     
2,079,987
 
                         
Non-Current Liabilities
                       
Loans and borrowings
   
7
     
788,591
     
408,783
 
Total Non-Current Liabilities
           
788,591
     
408,783
 
TOTAL LIABILITIES
           
2,620,722
     
2,488,770
 
                         
NET ASSETS
           
15,375,958
     
7,419,719
 
                         
EQUITY
                       
Contributed equity
   
8
     
44,914,632
     
29,782,268
 
Reserves
   
9
     
13,967,477
     
12,389,525
 
Accumulated losses
           
(43,506,151
)
   
(34,752,074
)
TOTAL EQUITY
           
15,375,958
     
7,419,719
 

The above Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.
 
IperionX Limited Financial Report for the Six Months Ended December 31, 2022
2

Condensed Consolidated Statement of Changes in Equity
FOR THE SIX MONTHS ENDED DECEMBER 31, 2022
graphic

   
Contributed
Equity
US$
   
Share- Based
Payments
Reserve
US$
   
Foreign
Currency
Translation
Reserve
US$
   
Accumulated
Losses
US$
   
Total
Equity
US$
 
                               
Balance at July 1, 2022
   
29,782,268
     
12,985,856
     
(596,331
)
   
(34,752,074
)
   
7,419,719
 
Net loss for the period
   
-
     
-
     
-
     
(8,754,077
)
   
(8,754,077
)
Exchange differences arising on translation of foreign operations
   
-
     
-
     
(102,645
)
   
-
     
(102,645
)
Total comprehensive loss
   
-
     
-
     
(102,645
)
   
(8,754,077
)
   
(8,856,722
)
Issue of shares - share placement
   
16,117,800
     
-
     
-
     
-
     
16,117,800
 
Issue of shares - exercise of options
   
194,205
     
(72,935
)
   
-
     
-
     
121,270
 
Issue of shares - conversion of RSUs
   
167,487
     
(167,487
)
   
-
     
-
     
-
 
Share issue costs
   
(1,347,128
)
   
354,788
     
-
     
-
     
(992,340
)
Share-based payment expense
   
-
     
1,566,231
     
-
     
-
     
1,566,231
 
Balance at December 31, 2022
   
44,914,632
     
14,666,453
     
(698,976
)
   
(43,506,151
)
   
15,375,958
 
                                         
Balance at July 1, 2021
   
10,255,369
     
4,738,007
     
(2,419
)
   
(13,230,837
)
   
1,760,120
 
Net loss for the period
   
-
     
-
     
-
     
(10,562,155
)
   
(10,562,155
)
Exchange differences arising on translation of foreign operations
   
-
     
-
     
(232,068
)
   
-
     
(232,068
)
Total comprehensive loss
   
-
     
-
     
(232,068
)
   
(10,562,155
)
   
(10,794,223
)
Issue of shares - share placement
   
17,604,000
     
-
     
-
     
-
     
17,604,000
 
Issue of shares - exercise of options
   
2,239,216
     
(92,479
)
   
-
     
-
     
2,146,737
 
Share issue costs
   
(428,812
)
   
-
     
-
     
-
     
(428,812
)
Share-based payment expense
   
-
     
4,764,135
     
-
     
-
     
4,764,135
 
Balance at December 31, 2021
   
29,669,773
     
9,409,663
     
(234,487
)
   
(23,792,992
)
   
15,051,957
 

The above Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

IperionX Limited Financial Report for the Six Months Ended December 31, 2022
3

Condensed Consolidated Statement of Cash Flows
FOR THE SIX MONTHS ENDED DECEMBER 31, 2022
graphic

   
Note
   
Six Months Ended
December 31, 2022
US$
   
Six Months Ended
December 31, 2021
US$
 
                   
Cash flows from operating activities
                 
Payments to suppliers and employees
         
(7,625,235
)
   
(5,892,972
)
Interest received
         
46,412
     
14,716
 
Interest paid
         
(12,137
)
   
(22,688
)
Net cash flows used in operating activities
         
(7,590,960
)
   
(5,900,944
)
                       
Cash flows from investing activities
                     
Purchase of exploration and evaluation assets
   
4
     
(418,200
)
   
(380,975
)
Purchase of property, plant and equipment
   
5
     
(1,179,703
)
   
(113,890
)
Purchase of financial assets
           
-
     
(250,000
)
Net cash flows used in investing activities
           
(1,597,903
)
   
(744,865
)
                         
Cash flows from financing activities
                       
Proceeds from issue of shares
           
16,239,070
     
19,750,737
 
Share issue costs
           
(992,340
)
   
(428,812
)
Repayment of borrowings
           
(2,751
)
   
-
 
Payment of principal portion of lease liabilities
           
(338,366
)
   
(26,626
)
Net cash flows from financing activities
           
14,905,613
     
19,295,299
 
                         
Net increase in cash and cash equivalents
           
5,716,750
     
12,649,490
 
Net foreign exchange differences
           
49,225
     
(91,036
)
Cash and cash equivalents at the beginning of the period
           
5,672,551
     
1,697,905
 
Cash and cash equivalents at the end of the period
           
11,438,526
     
14,256,359
 

The above Condensed Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

IperionX Limited Financial Report for the Six Months Ended December 31, 2022
4

Notes to the Condensed Consolidated Financial Statements
FOR THE SIX MONTHS ENDED DECEMBER 31, 2022
graphic


1.          SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Corporate information
 
IperionX Limited (“IperionX” or “Company”) is a for-profit company limited by shares, incorporated and domiciled in Australia. Our registered office is located at Level 9, 28 The Esplanade, Perth, Western Australia, 6000. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “IPX”, and our American Depository Shares, or ADSs, each representing ten (10) of our ordinary shares, are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “IPX”.
 
The principal activities of the Group during the six months ended December 31, 2022 consisted of the exploration and development of minerals and metals in the United States.
 
The unaudited interim condensed consolidated financial statements of IperionX and its subsidiaries (the “Consolidated Entity” or the “Group”) for the six months ended December 31, 2022 (the “Interim Financial Statements”) were authorised for issue in accordance with a resolution of the Directors on March 14, 2023.
 
Basis of preparation
 
The Interim Financial Statements have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting issued by the International Accounting Standard Board (“IASB”). The preparation of the Interim Financial Statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from those estimates.
 
The Interim Financial Statements do not include all the notes of the type normally included in annual financial statements and are not necessarily indicative of the results of operations and cash flows expected for the year ended June 30, 2023.  Accordingly, the Interim Financial Statements are to be read in conjunction with the annual consolidated financial statements of the Group for the year ended June 30, 2022. In the opinion of management, the accompanying Interim Financial Statements reflect all adjustments consisting only of normal recurring adjustments, which are necessary for a fair presentation of the financial results of such period. The financial report has been prepared on a historical cost basis and is presented in United States dollars ($).
 
The accounting policies and methods of computation adopted in the preparation of the Interim Financial Statements are consistent with those adopted and disclosed in the annual consolidated financial statements of the Group for the year ended June 30, 2022, except as disclosed below. These accounting policies are consistent with Australian Accounting Standards.
 
Going concern
 
The interim financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realization of assets and the settlement of liabilities in the normal course of business.
 
The Group had net cash outflows from operating and investing activities of US$9,188,863 for the six months ended December 31, 2022 (December 31, 2021: US$6,645,809). At December 31, 2022, the Group had cash and cash equivalents of US$11,438,526 (December 31, 2021: US$14,256,359).
 
The ongoing operation of the Group remains dependent upon raising further additional funding from shareholders or other parties. In light of the future expenditures to be incurred in executing on the Group’s current strategic plans to commercialize the Group’s titanium metal technologies and develop economically recoverable mineral deposits from the Group’s exploration properties, the Group is dependent on obtaining financing through equity financing, debt financing or other means. In the longer term, if the Group’s exploration, appraisal, and pilot activities are ultimately successful, additional funds will be required to develop the Group’s titanium metal technologies and exploration properties and commence commercial production. The ability to arrange such funding in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Group. There is no assurance that the Group will be successful in its efforts to raise additional funding on terms satisfactory to the Group. If the Group does not obtain additional funding, the Group may be required to delay, reduce the scope of, or eliminate its current or future exploration, appraisal, and pilot activities or relinquish rights to certain of its interests.

IperionX Limited Financial Report for the Six Months Ended December 31, 2022
5

1.          SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
 
Going concern (continued)
 

As a result of these matters, there is a material uncertainty that may cast substantial doubt about the Group’s ability to continue as a going concern and therefore the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. However, the Directors are confident that the Group will be able to raise additional funds as required to meet its obligations as and when they fall due and are of the opinion that the use of the going concern basis remains appropriate.
 
Comparative information
 
The Group has updated the classification of expenses to make the Statement of Profit or Loss and other Comprehensive Income more relevant to users of the financial statements. This has resulted in the reclassification of some expenses in the prior period, however, has not impacted the reported loss for the prior period or earnings per share.
 
New and amended standards and interpretations
 
In the current period, the Group has adopted all of the new and revised standards, interpretations and amendments that are relevant to its operations and effective for annual reporting periods beginning on or after July 1, 2022.
 
The new standards have not had a material effect on the Group’s financial statements.
 
The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
 

2.          SEGMENT INFORMATION
 
IFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Consolidated Entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance.
 
The Consolidated Entity operates in one segment, being exploration and development of minerals and metals in the United States.
 

3.          DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES
 
No dividend has been paid or provided for during the six months ended December 31, 2022 (December 31, 2021: nil).
 

4.          EXPLORATION AND EVALUATION ASSETS
 
   
Titan
Project
US$
 
December 31, 2022
     
Carrying value at July 1, 2022
   
2,431,229
 
Additions
   
418,200
 
Carrying amount at December 31, 2022 (1)
   
2,849,429
 
         
June 30, 2022
       
Carrying value at July 1, 2021
   
504,750
 
Additions
   
1,926,479
 
Carrying amount at June 30, 2022 (1)  
   
2,431,229
 
 

Notes:

(1)
The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.

IperionX Limited Financial Report for the Six Months Ended December 31, 2022
6


5.          PROPERTY, PLANT AND EQUIPMENT
 
   
Plant and equipment
US$
   
Right-of-use assets
US$
   
Total
US$
 
December 31, 2022
                 
Carrying value at July 1, 2022
   
922,118
     
465,868
     
1,387,986
 
Additions
   
1,179,703
     
950,537
     
2,130,240
 
Depreciation
   
(33,802
)
   
(115,325
)
   
(149,127
)
Carrying amount at December 31, 2022
   
2,068,019
     
1,301,080
     
3,369,099
 
- at cost
   
2,136,508
     
1,543,876
     
3,680,384
 
- accumulated depreciation
   
(68,489
)
   
(242,796
)
   
(311,285
)
                         
June 30, 2022
                       
Carrying value at July 1, 2021
   
65,858
     
473,761
     
539,619
 
Additions
   
889,988
     
140,188
     
1,030,176
 
Lease modifications
   
-
     
(28,375
)
   
(28,375
)
Depreciation
   
(33,728
)
   
(119,706
)
   
(153,434
)
Carrying amount at June 30, 2022
   
922,118
     
465,868
     
1,387,986
 
- at cost
   
956,805
     
593,339
     
1,550,144
 
- accumulated depreciation
   
(34,687
)
   
(127,471
)
   
(162,158
)
 

6.          TRADE AND OTHER PAYABLES
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Current
           
Trade payables
   
357,937
     
1,677,757
 
Accruals
   
395,508
     
196,450
 
Employee benefits
   
714,826
     
25,141
 
Total trade and other payables
   
1,468,271
     
1,899,348
 

IperionX Limited Financial Report for the Six Months Ended December 31, 2022
7


7.          LOANS AND BORROWINGS
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Current
           
Lease liabilities
   
358,112
     
128,653
 
Other loans and borrowings
   
5,748
     
5,594
 
Total current loans and borrowings 
   
363,860
     
134,247
 
                 
Non-current
               
Lease liabilities
   
760,633
     
377,920
 
Other loans and borrowings
   
27,958
     
30,863
 
Total non-current loans and borrowings 
   
788,591
     
408,783
 
                 
Total loans and borrowings
   
1,152,451
     
543,030
 
 

8.          CONTRIBUTED EQUITY
 
Issued capital
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
171,225,492 ordinary shares (June 30, 2022: 140,288,491)
   
44,914,632
     
29,782,268
 
     
44,914,632
     
29,782,268
 
 
Movements in issued capital
 
   
No. of
Ordinary
Shares
   
No. of Class A Performance Shares
   
No. of Class B Performance Shares
   
US$
 
December 31, 2022
                       
Opening balance at July 1, 2022
   
140,288,491
     
19,800,000
     
19,800,000
     
29,782,268
 
Issue of shares - share placement
   
30,000,000
     
-
     
-
     
16,117,800
 
Issue of shares - exercise of options
   
737,000
     
-
     
-
     
194,205
 
Conversion of RSUs
   
200,001
     
-
     
-
     
167,487
 
Share issue costs
   
-
     
-
     
-
     
(1,347,128
)
Closing balance at December 31, 2022
   
171,225,492
     
19,800,000
     
19,800,000
     
44,914,632
 
                                 
December 31, 2021
                               
Opening balance at July 1, 2021
   
105,105,787
     
19,800,000
     
19,800,000
     
10,255,369
 
Issue of shares - share placement
   
20,000,000
     
-
     
-
     
17,604,000
 
Issue of shares - exercise of options
   
14,382,704
     
-
     
-
     
2,239,216
 
Share issue costs
   
-
     
-
     
-
     
(428,812
)
Closing balance at December 31, 2021
   
139,488,491
     
19,800,000
     
19,800,000
     
29,669,773
 
IperionX Limited Financial Report for the Six Months Ended December 31, 2022
8


9.          RESERVES
 
Reserves
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Share based payments reserve
   
14,666,453
     
12,985,856
 
Foreign currency translation reserve
   
(698,976
)
   
(596,331
)
Total reserves
   
13,967,477
     
12,389,525
 
 
Movements in share based payments reserve
 
   
No. of
Listed
Options
   
No. of
Unlisted
Options
   
No. of Performance Rights
   
No. of
RSUs
   
US$
 
December 31, 2022
                             
Opening balance at July 1, 2022
   
-
     
23,824,000
     
27,620,000
     
600,000
     
12,985,856
 
Grant of employee incentive securities
   
-
     
424,372
     
1,135,000
     
424,372
     
-
 
Exercise of options
   
-
     
(737,000
)
   
-
     
-
     
(72,935
)
Conversion of RSUs
   
-
     
-
     
-
     
(200,001
)
   
(167,487
)
Grant of options to advisor
   
-
     
1,000,000
     
-
     
-
     
354,788
 
Share-based payments expense
   
-
     
-
     
-
     
-
      1,566,231  
Closing balance at December 31, 2022
   
-
     
24,511,372
     
28,755,000
     
824,371
     
14,666,453
 
                                         
December 31, 2021
                                       
Opening balance at July 1, 2021
   
12,624,214
     
25,800,000
     
16,325,000
     
-
     
4,738,007
 
Grant of employee incentive securities
   
-
     
600,000
     
8,990,000
     
600,000
     
-
 
Exercise of options
   
(12,606,704
)
   
(1,776,000
)
   
-
     
-
     
(92,479
)
Expiry of options
   
(17,510
)
   
-
     
-
     
-
     
-
 
Share-based payments expense
   
-
     
-
     
-
     
-
     
4,764,135
 
Closing balance at December 31, 2021
   
-
     
24,624,000
     
25,315,000
     
600,000
     
9,409,663
 
 

10.          SUBSIDIARIES
 
       
Equity Interest
 
Country of
Incorporation
 
December 31, 2022
%
   
June 30, 2022
%
 
IperionX Inc.
USA
   
100
%
   
100
%
IperionX Critical Minerals, LLC
USA
   
100
%
   
100
%
IperionX Technology, LLC
USA
   
100
%
   
100
%
Hyperion Metals (Australia) Pty Ltd
Australia
   
100
%
   
100
%
Calatos Pty Ltd, LLC
USA
   
100
%
   
100
%
 
IperionX Limited Financial Report for the Six Months Ended December 31, 2022
9


11.          CONTINGENT ASSETS AND LIABILITIES
 
Titan Project
At December 31, 2022, the Group had entered into exclusive option agreements with local landowners in Tennessee, United States, in relation to its Titan Project, which upon exercise, allows the Group to lease or, in some cases purchase, approximately 11,071 acres of surface property and the associated mineral rights from the local landowners. During the option period, our option agreements provide us with exclusive right to access, enter, occupy and use the surface property for all purposes related to exploring for and evaluating all minerals in return for making annual option payments and bonus payments during periods when we conduct drilling. Upon exercise, in the case of an option to lease, the Company will pay a production royalty to the landowners, subject to a minimum royalty. Upon exercise, in the case of a purchase, the Company will pay cash consideration approximating the fair market value of the property, excluding the value of any minerals, plus a premium.

Blacksand
At December 31, 2022, the Group had an exclusive option to purchase certain assets (including all intellectual property rights) of Blacksand Technology, LLC (“Blacksand”). Blacksand holds the exclusive commercial licensing rights for more than 40 global patents through a license agreement with the University of Utah including the global patents for patented technologies that can produce low-cost and low-carbon titanium metal. IperionX can exercise its option any time prior to 31 December 2024 (“Option Period”). As consideration for the option, IperionX shall make option payments to Blacksand totalling US$6,000,000 during the Option Period (US$1,500,000 payable in each of January 2023, July 2023, January 2024 and July 2024). If IperionX chooses to exercise its option, IperionX shall pay Blacksand: (1) any option payments that have not been paid at the date of exercise; and (2) an additional US$6,000,000. Subject to shareholder approval, IperionX may elect to satisfy 30% of the total purchase price through the issue of shares in IperionX. IperionX shall also commit to donate US$1,000,000 to establish an endowed chair professorship at the University of Utah in Dr. Fang’s name. If net sales from the acquired assets exceed US$300,000,000, then IperionX shall pay Blacksand a royalty equal to 0.5% of net sales in excess of US$300,000,000 for the life of the licensed patents. If IperionX chooses not to exercise its option, IperionX retains options to licence key technologies from Blacksand, including HAMR and GSD technologies that can produce low-cost and low-carbon titanium metal, for consideration comprising a license fee and a royalty.
 

12.          SUBSEQUENT EVENTS AFTER BALANCE DATE
 
(a)
On January 18, 2023, IperionX announced that it was the winner of the U.S. Department of Defense’s National Security Innovation Network (“NSIN”) Air Force Research Laboratory (“AFRL”) Grand Challenge contract. The winner of the Grand Challenge is eligible for a contract award up to US$500,000 across four phases.
 
Other than as outlined above, at the date of this report there are no other significant events occurring after balance date requiring disclosure.
 
IperionX Limited Financial Report for the Six Months Ended December 31, 2022
10

graphic

Forward Looking Statements
 
Information included in this release constitutes forward-looking statements. Often, but not always, forward looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “continue”, and “guidance”, or other similar words and may include, without limitation, statements regarding plans, strategies and objectives of management, anticipated production or construction commencement dates and expected costs or production outputs.
 
Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance, and achievements to differ materially from any future results, performance, or achievements. Relevant factors may include, but are not limited to, changes in commodity prices, foreign exchange fluctuations and general economic conditions, increased costs and demand for production inputs, the speculative nature of exploration and project development, including the risks of obtaining necessary licenses and permits and diminishing quantities or grades of reserves, political and social risks, changes to the regulatory framework within which the company operates or may in the future operate, environmental conditions including extreme weather conditions, recruitment and retention of personnel, industrial relations issues and litigation.
 
Forward looking statements are based on the Company and its management’s good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company’s business and operations in the future. The Company does not give any assurance that the assumptions on which forward looking statements are based will prove to be correct, or that the Company’s business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company’s control.
 
Although the Company attempts and has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in forward looking statements, there may be other factors that could cause actual results, performance, achievements, or events not to be as anticipated, estimated or intended, and many events are beyond the reasonable control of the Company. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements in these materials speak only at the date of issue. Subject to any continuing obligations under applicable law or any relevant stock exchange listing rules, in providing this information the company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.
 
Competent Persons Statement
 
The information in this document that relates to Exploration Results, Mineral Resources, Production Targets, Process Design, Mine Design, Cost Estimates, and Financial Analysis is extracted from IperionX’s ASX Announcement dated June 30, 2022 (“Original ASX Announcement”) which is available to view at IperionX’s website at www.iperionx.com. The Company confirms that a) it is not aware of any new information or data that materially affects the information included in the Original ASX Announcement; b) all material assumptions and technical parameters underpinning the Production Target, and related forecast financial information derived from the Production Target included in the Original ASX Announcement continue to apply and have not materially changed; and c) the form and context in which the relevant Competent Persons’ findings are presented in this report have not been materially changed from the Original ASX Announcement.
 

IperionX Limited Financial Report for the Six Months Ended December 31, 2022
11

v3.23.2
Document and Entity Information
6 Months Ended
Dec. 31, 2022
Cover [Abstract]  
Entity Registrant Name IPERIONX Ltd
Entity Central Index Key 0001898601
Current Fiscal Year End Date --06-30
Document Type 6-K
Amendment Flag false
Document Period End Date Dec. 31, 2022
v3.23.2
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income - USD ($)
6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Continuing operations    
Exploration and evaluation expenses $ (1,517,474) $ (2,734,807)
Research and development costs (2,099,309) (696,715)
Corporate and administrative expenses (2,161,671) (998,378)
Business development expenses (1,333,073) (1,501,724)
Share-based payment expense (1,566,231) (4,764,135)
Finance income 198,282 157,435
Finance costs (30,717) (23,831)
Other income and expenses (243,884) 0
Loss before income tax (8,754,077) (10,562,155)
Income tax expense 0 0
Loss for the period (8,754,077) (10,562,155)
Loss attributable to members of IperionX Limited (8,754,077) (10,562,155)
Items that may be reclassified subsequently to profit or loss:    
Exchange differences arising on translation of foreign operations (102,645) (232,068)
Other comprehensive loss for the period, net of tax (102,645) (232,068)
Total comprehensive loss for the period (8,856,722) (10,794,223)
Total comprehensive loss attributable to members of IperionX Limited $ (8,856,722) $ (10,794,223)
Loss per share    
Basic loss per share (in dollars per share) $ (0.06) $ (0.08)
Diluted loss per share (in dollars per share) $ (0.06) $ (0.08)
v3.23.2
Condensed Consolidated Statement of Financial Position - USD ($)
Dec. 31, 2022
Jun. 30, 2022
Current Assets    
Cash and cash equivalents $ 11,438,526 $ 5,672,551
Trade and other receivables 84,477 22,540
Prepayments 255,149 144,183
Total Current Assets 11,778,152 5,839,274
Non-Current Assets    
Exploration and evaluation assets 2,849,429 2,431,229
Property, plant and equipment 3,369,099 1,387,986
Financial assets 0 250,000
Total Non-Current Assets 6,218,528 4,069,215
TOTAL ASSETS 17,996,680 9,908,489
Current Liabilities    
Trade and other payables 1,468,271 1,899,348
Loans and borrowings 363,860 134,247
Provisions 0 46,392
Total Current Liabilities 1,832,131 2,079,987
Non-Current Liabilities    
Loans and borrowings 788,591 408,783
Total Non-Current Liabilities 788,591 408,783
TOTAL LIABILITIES 2,620,722 2,488,770
NET ASSETS 15,375,958 7,419,719
EQUITY    
Contributed equity 44,914,632 29,782,268
Reserves 13,967,477 12,389,525
Accumulated losses (43,506,151) (34,752,074)
TOTAL EQUITY $ 15,375,958 $ 7,419,719
v3.23.2
Condensed Consolidated Statement of Changes in Equity - USD ($)
Total
Contributed Equity [Member]
Share-Based Payments Reserve [Member]
Foreign Currency Translation Reserve [Member]
Accumulated Losses [Member]
Beginning balance at Jun. 30, 2021 $ 1,760,120 $ 10,255,369 $ 4,738,007 $ (2,419) $ (13,230,837)
Changes in equity          
Net loss for the period (10,562,155) 0 0 0 (10,562,155)
Exchange differences arising on translation of foreign operations (232,068) 0 0 (232,068) 0
Total comprehensive loss for the period (10,794,223) 0 0 (232,068) (10,562,155)
Issue of shares - share placement 17,604,000 17,604,000 0 0 0
Issue of shares - exercise of options 2,146,737 2,239,216 (92,479) 0 0
Share issue costs (428,812) (428,812) 0 0 0
Share-based payment expense 4,764,135 0 4,764,135 0 0
Ending balance at Dec. 31, 2021 15,051,957 29,669,773 9,409,663 (234,487) (23,792,992)
Beginning balance at Jun. 30, 2022 7,419,719 29,782,268 12,985,856 (596,331) (34,752,074)
Changes in equity          
Net loss for the period (8,754,077) 0 0 0 (8,754,077)
Exchange differences arising on translation of foreign operations (102,645) 0 0 (102,645) 0
Total comprehensive loss for the period (8,856,722) 0 0 (102,645) (8,754,077)
Issue of shares - share placement 16,117,800 16,117,800 0 0 0
Issue of shares - exercise of options 121,270 194,205 (72,935) 0 0
Issue of shares - conversion of RSUs 0 167,487 (167,487) 0 0
Share issue costs (992,340) (1,347,128) 354,788 0 0
Share-based payment expense 1,566,231 0 1,566,231 0 0
Ending balance at Dec. 31, 2022 $ 15,375,958 $ 44,914,632 $ 14,666,453 $ (698,976) $ (43,506,151)
v3.23.2
Condensed Consolidated Statement of Cash Flows - USD ($)
6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities    
Payments to suppliers and employees $ (7,625,235) $ (5,892,972)
Interest received 46,412 14,716
Interest paid (12,137) (22,688)
Net cash flows used in operating activities (7,590,960) (5,900,944)
Cash flows from investing activities    
Purchase of exploration and evaluation assets (418,200) (380,975)
Purchase of property, plant and equipment (1,179,703) (113,890)
Purchase of financial assets 0 (250,000)
Net cash flows used in investing activities (1,597,903) (744,865)
Cash flows from financing activities    
Proceeds from issue of shares 16,239,070 19,750,737
Share issue costs (992,340) (428,812)
Repayment of borrowings (2,751) 0
Payment of principal portion of lease liabilities (338,366) (26,626)
Net cash flows from financing activities 14,905,613 19,295,299
Net increase in cash and cash equivalents 5,716,750 12,649,490
Net foreign exchange differences 49,225 (91,036)
Cash and cash equivalents at the beginning of the period 5,672,551 1,697,905
Cash and cash equivalents at the end of the period $ 11,438,526 $ 14,256,359
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


1.          SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Corporate information
 
IperionX Limited (“IperionX” or “Company”) is a for-profit company limited by shares, incorporated and domiciled in Australia. Our registered office is located at Level 9, 28 The Esplanade, Perth, Western Australia, 6000. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “IPX”, and our American Depository Shares, or ADSs, each representing ten (10) of our ordinary shares, are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “IPX”.
 
The principal activities of the Group during the six months ended December 31, 2022 consisted of the exploration and development of minerals and metals in the United States.
 
The unaudited interim condensed consolidated financial statements of IperionX and its subsidiaries (the “Consolidated Entity” or the “Group”) for the six months ended December 31, 2022 (the “Interim Financial Statements”) were authorised for issue in accordance with a resolution of the Directors on March 14, 2023.
 
Basis of preparation
 
The Interim Financial Statements have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting issued by the International Accounting Standard Board (“IASB”). The preparation of the Interim Financial Statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from those estimates.
 
The Interim Financial Statements do not include all the notes of the type normally included in annual financial statements and are not necessarily indicative of the results of operations and cash flows expected for the year ended June 30, 2023.  Accordingly, the Interim Financial Statements are to be read in conjunction with the annual consolidated financial statements of the Group for the year ended June 30, 2022. In the opinion of management, the accompanying Interim Financial Statements reflect all adjustments consisting only of normal recurring adjustments, which are necessary for a fair presentation of the financial results of such period. The financial report has been prepared on a historical cost basis and is presented in United States dollars ($).
 
The accounting policies and methods of computation adopted in the preparation of the Interim Financial Statements are consistent with those adopted and disclosed in the annual consolidated financial statements of the Group for the year ended June 30, 2022, except as disclosed below. These accounting policies are consistent with Australian Accounting Standards.
 
Going concern
 
The interim financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realization of assets and the settlement of liabilities in the normal course of business.
 
The Group had net cash outflows from operating and investing activities of US$9,188,863 for the six months ended December 31, 2022 (December 31, 2021: US$6,645,809). At December 31, 2022, the Group had cash and cash equivalents of US$11,438,526 (December 31, 2021: US$14,256,359).
 
The ongoing operation of the Group remains dependent upon raising further additional funding from shareholders or other parties. In light of the future expenditures to be incurred in executing on the Group’s current strategic plans to commercialize the Group’s titanium metal technologies and develop economically recoverable mineral deposits from the Group’s exploration properties, the Group is dependent on obtaining financing through equity financing, debt financing or other means. In the longer term, if the Group’s exploration, appraisal, and pilot activities are ultimately successful, additional funds will be required to develop the Group’s titanium metal technologies and exploration properties and commence commercial production. The ability to arrange such funding in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Group. There is no assurance that the Group will be successful in its efforts to raise additional funding on terms satisfactory to the Group. If the Group does not obtain additional funding, the Group may be required to delay, reduce the scope of, or eliminate its current or future exploration, appraisal, and pilot activities or relinquish rights to certain of its interests.

As a result of these matters, there is a material uncertainty that may cast substantial doubt about the Group’s ability to continue as a going concern and therefore the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. However, the Directors are confident that the Group will be able to raise additional funds as required to meet its obligations as and when they fall due and are of the opinion that the use of the going concern basis remains appropriate.
 
Comparative information
 
The Group has updated the classification of expenses to make the Statement of Profit or Loss and other Comprehensive Income more relevant to users of the financial statements. This has resulted in the reclassification of some expenses in the prior period, however, has not impacted the reported loss for the prior period or earnings per share.
 
New and amended standards and interpretations
 
In the current period, the Group has adopted all of the new and revised standards, interpretations and amendments that are relevant to its operations and effective for annual reporting periods beginning on or after July 1, 2022.
 
The new standards have not had a material effect on the Group’s financial statements.
 
The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
v3.23.2
SEGMENT INFORMATION
6 Months Ended
Dec. 31, 2022
SEGMENT INFORMATION [Abstract]  
SEGMENT INFORMATION

2.          SEGMENT INFORMATION
 
IFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Consolidated Entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance.
 
The Consolidated Entity operates in one segment, being exploration and development of minerals and metals in the United States.
v3.23.2
DIVIDENDS PAID OR PROVIDED FOR
6 Months Ended
Dec. 31, 2022
DIVIDENDS PAID OR PROVIDED FOR [Abstract]  
DIVIDENDS PAID OR PROVIDED FOR

3.          DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES
 
No dividend has been paid or provided for during the six months ended December 31, 2022 (December 31, 2021: nil).
v3.23.2
EXPLORATION AND EVALUATION ASSETS
6 Months Ended
Dec. 31, 2022
EXPLORATION AND EVALUATION ASSETS [Abstract]  
EXPLORATION AND EVALUATION ASSETS

4.          EXPLORATION AND EVALUATION ASSETS
 
   
Titan
Project
US$
 
December 31, 2022
     
Carrying value at July 1, 2022
   
2,431,229
 
Additions
   
418,200
 
Carrying amount at December 31, 2022 (1)
   
2,849,429
 
         
June 30, 2022
       
Carrying value at July 1, 2021
   
504,750
 
Additions
   
1,926,479
 
Carrying amount at June 30, 2022 (1)  
   
2,431,229
 
 

Notes:

(1)
The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.
v3.23.2
PROPERTY, PLANT AND EQUIPMENT
6 Months Ended
Dec. 31, 2022
PROPERTY, PLANT AND EQUIPMENT [Abstract]  
PROPERTY, PLANT AND EQUIPMENT

5.          PROPERTY, PLANT AND EQUIPMENT
 
   
Plant and equipment
US$
   
Right-of-use assets
US$
   
Total
US$
 
December 31, 2022
                 
Carrying value at July 1, 2022
   
922,118
     
465,868
     
1,387,986
 
Additions
   
1,179,703
     
950,537
     
2,130,240
 
Depreciation
   
(33,802
)
   
(115,325
)
   
(149,127
)
Carrying amount at December 31, 2022
   
2,068,019
     
1,301,080
     
3,369,099
 
- at cost
   
2,136,508
     
1,543,876
     
3,680,384
 
- accumulated depreciation
   
(68,489
)
   
(242,796
)
   
(311,285
)
                         
June 30, 2022
                       
Carrying value at July 1, 2021
   
65,858
     
473,761
     
539,619
 
Additions
   
889,988
     
140,188
     
1,030,176
 
Lease modifications
   
-
     
(28,375
)
   
(28,375
)
Depreciation
   
(33,728
)
   
(119,706
)
   
(153,434
)
Carrying amount at June 30, 2022
   
922,118
     
465,868
     
1,387,986
 
- at cost
   
956,805
     
593,339
     
1,550,144
 
- accumulated depreciation
   
(34,687
)
   
(127,471
)
   
(162,158
)
v3.23.2
TRADE AND OTHER PAYABLES
6 Months Ended
Dec. 31, 2022
TRADE AND OTHER PAYABLES [Abstract]  
TRADE AND OTHER PAYABLES

6.          TRADE AND OTHER PAYABLES
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Current
           
Trade payables
   
357,937
     
1,677,757
 
Accruals
   
395,508
     
196,450
 
Employee benefits
   
714,826
     
25,141
 
Total trade and other payables
   
1,468,271
     
1,899,348
 
v3.23.2
LOANS AND BORROWINGS
6 Months Ended
Dec. 31, 2022
LOANS AND BORROWINGS [Abstract]  
LOANS AND BORROWINGS

7.          LOANS AND BORROWINGS
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Current
           
Lease liabilities
   
358,112
     
128,653
 
Other loans and borrowings
   
5,748
     
5,594
 
Total current loans and borrowings 
   
363,860
     
134,247
 
                 
Non-current
               
Lease liabilities
   
760,633
     
377,920
 
Other loans and borrowings
   
27,958
     
30,863
 
Total non-current loans and borrowings 
   
788,591
     
408,783
 
                 
Total loans and borrowings
   
1,152,451
     
543,030
 
v3.23.2
CONTRIBUTED EQUITY
6 Months Ended
Dec. 31, 2022
CONTRIBUTED EQUITY [Abstract]  
CONTRIBUTED EQUITY

8.          CONTRIBUTED EQUITY
 
Issued capital
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
171,225,492 ordinary shares (June 30, 2022: 140,288,491)
   
44,914,632
     
29,782,268
 
     
44,914,632
     
29,782,268
 
 
Movements in issued capital
 
   
No. of
Ordinary
Shares
   
No. of Class A Performance Shares
   
No. of Class B Performance Shares
   
US$
 
December 31, 2022
                       
Opening balance at July 1, 2022
   
140,288,491
     
19,800,000
     
19,800,000
     
29,782,268
 
Issue of shares - share placement
   
30,000,000
     
-
     
-
     
16,117,800
 
Issue of shares - exercise of options
   
737,000
     
-
     
-
     
194,205
 
Conversion of RSUs
   
200,001
     
-
     
-
     
167,487
 
Share issue costs
   
-
     
-
     
-
     
(1,347,128
)
Closing balance at December 31, 2022
   
171,225,492
     
19,800,000
     
19,800,000
     
44,914,632
 
                                 
December 31, 2021
                               
Opening balance at July 1, 2021
   
105,105,787
     
19,800,000
     
19,800,000
     
10,255,369
 
Issue of shares - share placement
   
20,000,000
     
-
     
-
     
17,604,000
 
Issue of shares - exercise of options
   
14,382,704
     
-
     
-
     
2,239,216
 
Share issue costs
   
-
     
-
     
-
     
(428,812
)
Closing balance at December 31, 2021
   
139,488,491
     
19,800,000
     
19,800,000
     
29,669,773
 
v3.23.2
RESERVES
6 Months Ended
Dec. 31, 2022
RESERVES [Abstract]  
RESERVES

9.          RESERVES
 
Reserves
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Share based payments reserve
   
14,666,453
     
12,985,856
 
Foreign currency translation reserve
   
(698,976
)
   
(596,331
)
Total reserves
   
13,967,477
     
12,389,525
 
 
Movements in share based payments reserve
 
   
No. of
Listed
Options
   
No. of
Unlisted
Options
   
No. of Performance Rights
   
No. of
RSUs
   
US$
 
December 31, 2022
                             
Opening balance at July 1, 2022
   
-
     
23,824,000
     
27,620,000
     
600,000
     
12,985,856
 
Grant of employee incentive securities
   
-
     
424,372
     
1,135,000
     
424,372
     
-
 
Exercise of options
   
-
     
(737,000
)
   
-
     
-
     
(72,935
)
Conversion of RSUs
   
-
     
-
     
-
     
(200,001
)
   
(167,487
)
Grant of options to advisor
   
-
     
1,000,000
     
-
     
-
     
354,788
 
Share-based payments expense
   
-
     
-
     
-
     
-
      1,566,231  
Closing balance at December 31, 2022
   
-
     
24,511,372
     
28,755,000
     
824,371
     
14,666,453
 
                                         
December 31, 2021
                                       
Opening balance at July 1, 2021
   
12,624,214
     
25,800,000
     
16,325,000
     
-
     
4,738,007
 
Grant of employee incentive securities
   
-
     
600,000
     
8,990,000
     
600,000
     
-
 
Exercise of options
   
(12,606,704
)
   
(1,776,000
)
   
-
     
-
     
(92,479
)
Expiry of options
   
(17,510
)
   
-
     
-
     
-
     
-
 
Share-based payments expense
   
-
     
-
     
-
     
-
     
4,764,135
 
Closing balance at December 31, 2021
   
-
     
24,624,000
     
25,315,000
     
600,000
     
9,409,663
 
v3.23.2
SUBSIDIARIES
6 Months Ended
Dec. 31, 2022
SUBSIDIARIES [Abstract]  
SUBSIDIARIES

10.          SUBSIDIARIES
 
       
Equity Interest
 
Country of
Incorporation
 
December 31, 2022
%
   
June 30, 2022
%
 
IperionX Inc.
USA
   
100
%
   
100
%
IperionX Critical Minerals, LLC
USA
   
100
%
   
100
%
IperionX Technology, LLC
USA
   
100
%
   
100
%
Hyperion Metals (Australia) Pty Ltd
Australia
   
100
%
   
100
%
Calatos Pty Ltd, LLC
USA
   
100
%
   
100
%
v3.23.2
CONTINGENT ASSETS AND LIABILITIES
6 Months Ended
Dec. 31, 2022
CONTINGENT ASSETS AND LIABILITIES [Abstract]  
CONTINGENT ASSETS AND LIABILITIES

11.          CONTINGENT ASSETS AND LIABILITIES
 
Titan Project
At December 31, 2022, the Group had entered into exclusive option agreements with local landowners in Tennessee, United States, in relation to its Titan Project, which upon exercise, allows the Group to lease or, in some cases purchase, approximately 11,071 acres of surface property and the associated mineral rights from the local landowners. During the option period, our option agreements provide us with exclusive right to access, enter, occupy and use the surface property for all purposes related to exploring for and evaluating all minerals in return for making annual option payments and bonus payments during periods when we conduct drilling. Upon exercise, in the case of an option to lease, the Company will pay a production royalty to the landowners, subject to a minimum royalty. Upon exercise, in the case of a purchase, the Company will pay cash consideration approximating the fair market value of the property, excluding the value of any minerals, plus a premium.

Blacksand
At December 31, 2022, the Group had an exclusive option to purchase certain assets (including all intellectual property rights) of Blacksand Technology, LLC (“Blacksand”). Blacksand holds the exclusive commercial licensing rights for more than 40 global patents through a license agreement with the University of Utah including the global patents for patented technologies that can produce low-cost and low-carbon titanium metal. IperionX can exercise its option any time prior to 31 December 2024 (“Option Period”). As consideration for the option, IperionX shall make option payments to Blacksand totalling US$6,000,000 during the Option Period (US$1,500,000 payable in each of January 2023, July 2023, January 2024 and July 2024). If IperionX chooses to exercise its option, IperionX shall pay Blacksand: (1) any option payments that have not been paid at the date of exercise; and (2) an additional US$6,000,000. Subject to shareholder approval, IperionX may elect to satisfy 30% of the total purchase price through the issue of shares in IperionX. IperionX shall also commit to donate US$1,000,000 to establish an endowed chair professorship at the University of Utah in Dr. Fang’s name. If net sales from the acquired assets exceed US$300,000,000, then IperionX shall pay Blacksand a royalty equal to 0.5% of net sales in excess of US$300,000,000 for the life of the licensed patents. If IperionX chooses not to exercise its option, IperionX retains options to licence key technologies from Blacksand, including HAMR and GSD technologies that can produce low-cost and low-carbon titanium metal, for consideration comprising a license fee and a royalty.
v3.23.2
SUBSEQUENT EVENTS AFTER BALANCE DATE
6 Months Ended
Dec. 31, 2022
SUBSEQUENT EVENTS AFTER BALANCE DATE [Abstract]  
SUBSEQUENT EVENTS AFTER BALANCE DATE [Text Block]

12.          SUBSEQUENT EVENTS AFTER BALANCE DATE
 
(a)
On January 18, 2023, IperionX announced that it was the winner of the U.S. Department of Defense’s National Security Innovation Network (“NSIN”) Air Force Research Laboratory (“AFRL”) Grand Challenge contract. The winner of the Grand Challenge is eligible for a contract award up to US$500,000 across four phases.
 
Other than as outlined above, at the date of this report there are no other significant events occurring after balance date requiring disclosure.
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Corporate information
Corporate information
 
IperionX Limited (“IperionX” or “Company”) is a for-profit company limited by shares, incorporated and domiciled in Australia. Our registered office is located at Level 9, 28 The Esplanade, Perth, Western Australia, 6000. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “IPX”, and our American Depository Shares, or ADSs, each representing ten (10) of our ordinary shares, are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “IPX”.
 
The principal activities of the Group during the six months ended December 31, 2022 consisted of the exploration and development of minerals and metals in the United States.
 
The unaudited interim condensed consolidated financial statements of IperionX and its subsidiaries (the “Consolidated Entity” or the “Group”) for the six months ended December 31, 2022 (the “Interim Financial Statements”) were authorised for issue in accordance with a resolution of the Directors on March 14, 2023.
Basis of preparation
Basis of preparation
 
The Interim Financial Statements have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting issued by the International Accounting Standard Board (“IASB”). The preparation of the Interim Financial Statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from those estimates.
 
The Interim Financial Statements do not include all the notes of the type normally included in annual financial statements and are not necessarily indicative of the results of operations and cash flows expected for the year ended June 30, 2023.  Accordingly, the Interim Financial Statements are to be read in conjunction with the annual consolidated financial statements of the Group for the year ended June 30, 2022. In the opinion of management, the accompanying Interim Financial Statements reflect all adjustments consisting only of normal recurring adjustments, which are necessary for a fair presentation of the financial results of such period. The financial report has been prepared on a historical cost basis and is presented in United States dollars ($).
 
The accounting policies and methods of computation adopted in the preparation of the Interim Financial Statements are consistent with those adopted and disclosed in the annual consolidated financial statements of the Group for the year ended June 30, 2022, except as disclosed below. These accounting policies are consistent with Australian Accounting Standards.
 
Going concern
 
The interim financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realization of assets and the settlement of liabilities in the normal course of business.
 
The Group had net cash outflows from operating and investing activities of US$9,188,863 for the six months ended December 31, 2022 (December 31, 2021: US$6,645,809). At December 31, 2022, the Group had cash and cash equivalents of US$11,438,526 (December 31, 2021: US$14,256,359).
 
The ongoing operation of the Group remains dependent upon raising further additional funding from shareholders or other parties. In light of the future expenditures to be incurred in executing on the Group’s current strategic plans to commercialize the Group’s titanium metal technologies and develop economically recoverable mineral deposits from the Group’s exploration properties, the Group is dependent on obtaining financing through equity financing, debt financing or other means. In the longer term, if the Group’s exploration, appraisal, and pilot activities are ultimately successful, additional funds will be required to develop the Group’s titanium metal technologies and exploration properties and commence commercial production. The ability to arrange such funding in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Group. There is no assurance that the Group will be successful in its efforts to raise additional funding on terms satisfactory to the Group. If the Group does not obtain additional funding, the Group may be required to delay, reduce the scope of, or eliminate its current or future exploration, appraisal, and pilot activities or relinquish rights to certain of its interests.

As a result of these matters, there is a material uncertainty that may cast substantial doubt about the Group’s ability to continue as a going concern and therefore the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. However, the Directors are confident that the Group will be able to raise additional funds as required to meet its obligations as and when they fall due and are of the opinion that the use of the going concern basis remains appropriate.
 
Comparative information
 
The Group has updated the classification of expenses to make the Statement of Profit or Loss and other Comprehensive Income more relevant to users of the financial statements. This has resulted in the reclassification of some expenses in the prior period, however, has not impacted the reported loss for the prior period or earnings per share.
New and amended standards and interpretations
New and amended standards and interpretations
 
In the current period, the Group has adopted all of the new and revised standards, interpretations and amendments that are relevant to its operations and effective for annual reporting periods beginning on or after July 1, 2022.
 
The new standards have not had a material effect on the Group’s financial statements.
 
The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
v3.23.2
EXPLORATION AND EVALUATION ASSETS (Tables)
6 Months Ended
Dec. 31, 2022
EXPLORATION AND EVALUATION ASSETS [Abstract]  
Exploration and Evaluation Assets
   
Titan
Project
US$
 
December 31, 2022
     
Carrying value at July 1, 2022
   
2,431,229
 
Additions
   
418,200
 
Carrying amount at December 31, 2022 (1)
   
2,849,429
 
         
June 30, 2022
       
Carrying value at July 1, 2021
   
504,750
 
Additions
   
1,926,479
 
Carrying amount at June 30, 2022 (1)  
   
2,431,229
 
 

Notes:

(1)
The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.
v3.23.2
PROPERTY, PLANT AND EQUIPMENT (Tables)
6 Months Ended
Dec. 31, 2022
PROPERTY, PLANT AND EQUIPMENT [Abstract]  
Property, Plant and Equipment
   
Plant and equipment
US$
   
Right-of-use assets
US$
   
Total
US$
 
December 31, 2022
                 
Carrying value at July 1, 2022
   
922,118
     
465,868
     
1,387,986
 
Additions
   
1,179,703
     
950,537
     
2,130,240
 
Depreciation
   
(33,802
)
   
(115,325
)
   
(149,127
)
Carrying amount at December 31, 2022
   
2,068,019
     
1,301,080
     
3,369,099
 
- at cost
   
2,136,508
     
1,543,876
     
3,680,384
 
- accumulated depreciation
   
(68,489
)
   
(242,796
)
   
(311,285
)
                         
June 30, 2022
                       
Carrying value at July 1, 2021
   
65,858
     
473,761
     
539,619
 
Additions
   
889,988
     
140,188
     
1,030,176
 
Lease modifications
   
-
     
(28,375
)
   
(28,375
)
Depreciation
   
(33,728
)
   
(119,706
)
   
(153,434
)
Carrying amount at June 30, 2022
   
922,118
     
465,868
     
1,387,986
 
- at cost
   
956,805
     
593,339
     
1,550,144
 
- accumulated depreciation
   
(34,687
)
   
(127,471
)
   
(162,158
)
v3.23.2
TRADE AND OTHER PAYABLES (Tables)
6 Months Ended
Dec. 31, 2022
TRADE AND OTHER PAYABLES [Abstract]  
Trade and Other Payables
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Current
           
Trade payables
   
357,937
     
1,677,757
 
Accruals
   
395,508
     
196,450
 
Employee benefits
   
714,826
     
25,141
 
Total trade and other payables
   
1,468,271
     
1,899,348
 
v3.23.2
LOANS AND BORROWINGS (Tables)
6 Months Ended
Dec. 31, 2022
LOANS AND BORROWINGS [Abstract]  
Loans and Borrowings
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Current
           
Lease liabilities
   
358,112
     
128,653
 
Other loans and borrowings
   
5,748
     
5,594
 
Total current loans and borrowings 
   
363,860
     
134,247
 
                 
Non-current
               
Lease liabilities
   
760,633
     
377,920
 
Other loans and borrowings
   
27,958
     
30,863
 
Total non-current loans and borrowings 
   
788,591
     
408,783
 
                 
Total loans and borrowings
   
1,152,451
     
543,030
 
v3.23.2
CONTRIBUTED EQUITY (Tables)
6 Months Ended
Dec. 31, 2022
CONTRIBUTED EQUITY [Abstract]  
Issued Capital
Issued capital
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
171,225,492 ordinary shares (June 30, 2022: 140,288,491)
   
44,914,632
     
29,782,268
 
     
44,914,632
     
29,782,268
 
Movements in Issued Capital
Movements in issued capital
 
   
No. of
Ordinary
Shares
   
No. of Class A Performance Shares
   
No. of Class B Performance Shares
   
US$
 
December 31, 2022
                       
Opening balance at July 1, 2022
   
140,288,491
     
19,800,000
     
19,800,000
     
29,782,268
 
Issue of shares - share placement
   
30,000,000
     
-
     
-
     
16,117,800
 
Issue of shares - exercise of options
   
737,000
     
-
     
-
     
194,205
 
Conversion of RSUs
   
200,001
     
-
     
-
     
167,487
 
Share issue costs
   
-
     
-
     
-
     
(1,347,128
)
Closing balance at December 31, 2022
   
171,225,492
     
19,800,000
     
19,800,000
     
44,914,632
 
                                 
December 31, 2021
                               
Opening balance at July 1, 2021
   
105,105,787
     
19,800,000
     
19,800,000
     
10,255,369
 
Issue of shares - share placement
   
20,000,000
     
-
     
-
     
17,604,000
 
Issue of shares - exercise of options
   
14,382,704
     
-
     
-
     
2,239,216
 
Share issue costs
   
-
     
-
     
-
     
(428,812
)
Closing balance at December 31, 2021
   
139,488,491
     
19,800,000
     
19,800,000
     
29,669,773
 
v3.23.2
RESERVES (Tables)
6 Months Ended
Dec. 31, 2022
RESERVES [Abstract]  
Reserves
Reserves
 
   
December 31, 2022
US$
   
June 30, 2022
US$
 
Share based payments reserve
   
14,666,453
     
12,985,856
 
Foreign currency translation reserve
   
(698,976
)
   
(596,331
)
Total reserves
   
13,967,477
     
12,389,525
 
Movements in Share-based Payments Reserve
Movements in share based payments reserve
 
   
No. of
Listed
Options
   
No. of
Unlisted
Options
   
No. of Performance Rights
   
No. of
RSUs
   
US$
 
December 31, 2022
                             
Opening balance at July 1, 2022
   
-
     
23,824,000
     
27,620,000
     
600,000
     
12,985,856
 
Grant of employee incentive securities
   
-
     
424,372
     
1,135,000
     
424,372
     
-
 
Exercise of options
   
-
     
(737,000
)
   
-
     
-
     
(72,935
)
Conversion of RSUs
   
-
     
-
     
-
     
(200,001
)
   
(167,487
)
Grant of options to advisor
   
-
     
1,000,000
     
-
     
-
     
354,788
 
Share-based payments expense
   
-
     
-
     
-
     
-
      1,566,231  
Closing balance at December 31, 2022
   
-
     
24,511,372
     
28,755,000
     
824,371
     
14,666,453
 
                                         
December 31, 2021
                                       
Opening balance at July 1, 2021
   
12,624,214
     
25,800,000
     
16,325,000
     
-
     
4,738,007
 
Grant of employee incentive securities
   
-
     
600,000
     
8,990,000
     
600,000
     
-
 
Exercise of options
   
(12,606,704
)
   
(1,776,000
)
   
-
     
-
     
(92,479
)
Expiry of options
   
(17,510
)
   
-
     
-
     
-
     
-
 
Share-based payments expense
   
-
     
-
     
-
     
-
     
4,764,135
 
Closing balance at December 31, 2021
   
-
     
24,624,000
     
25,315,000
     
600,000
     
9,409,663
 
v3.23.2
SUBSIDIARIES (Tables)
6 Months Ended
Dec. 31, 2022
SUBSIDIARIES [Abstract]  
Subsidiaries
       
Equity Interest
 
Country of
Incorporation
 
December 31, 2022
%
   
June 30, 2022
%
 
IperionX Inc.
USA
   
100
%
   
100
%
IperionX Critical Minerals, LLC
USA
   
100
%
   
100
%
IperionX Technology, LLC
USA
   
100
%
   
100
%
Hyperion Metals (Australia) Pty Ltd
Australia
   
100
%
   
100
%
Calatos Pty Ltd, LLC
USA
   
100
%
   
100
%
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Corporate information (Details)
Dec. 31, 2022
shares
Corporate information [Abstract]  
Number of ordinary shares listed on each securities exchange (in shares) 10
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Basis of Preparation (Details) - USD ($)
6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Basis of preparation [Abstract]        
Net cash outflows from operating and investing activities $ 9,188,863 $ 6,645,809    
Cash and cash equivalents $ 11,438,526 $ 14,256,359 $ 5,672,551 $ 1,697,905
v3.23.2
SEGMENT INFORMATION (Details)
6 Months Ended
Dec. 31, 2022
Segment
SEGMENT INFORMATION [Abstract]  
Number of operating segments 1
v3.23.2
DIVIDENDS PAID OR PROVIDED FOR (Details) - USD ($)
6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
DIVIDENDS PAID OR PROVIDED FOR [Abstract]    
Dividends paid $ 0 $ 0
Dividends proposed $ 0 $ 0
v3.23.2
EXPLORATION AND EVALUATION ASSETS (Details) - USD ($)
6 Months Ended 12 Months Ended
Dec. 31, 2022
Jun. 30, 2022
Exploration And Evaluation Assets [Roll Forward]    
Carrying amount, beginning balance $ 2,431,229  
Carrying amount, ending balance 2,849,429 $ 2,431,229
Titan Project [Member]    
Exploration And Evaluation Assets [Roll Forward]    
Carrying amount, beginning balance 2,431,229 [1] 504,750
Additions 418,200 1,926,479
Carrying amount, ending balance [1] $ 2,849,429 $ 2,431,229
[1] The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.
v3.23.2
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)
6 Months Ended 12 Months Ended
Dec. 31, 2022
Jun. 30, 2022
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance $ 1,387,986 $ 539,619
Additions 2,130,240 1,030,176
Lease modifications   (28,375)
Depreciation (149,127) (153,434)
Carrying amount, ending balance 3,369,099 1,387,986
At Cost [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance 1,550,144  
Carrying amount, ending balance 3,680,384 1,550,144
Accumulated Depreciation [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance (162,158)  
Carrying amount, ending balance (311,285) (162,158)
Plant and Equipment [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance 922,118 65,858
Additions 1,179,703 889,988
Lease modifications   0
Depreciation (33,802) (33,728)
Carrying amount, ending balance 2,068,019 922,118
Plant and Equipment [Member] | At Cost [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance 956,805  
Carrying amount, ending balance 2,136,508 956,805
Plant and Equipment [Member] | Accumulated Depreciation [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance (34,687)  
Carrying amount, ending balance (68,489) (34,687)
Right-of-use Assets [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance 465,868 473,761
Additions 950,537 140,188
Lease modifications   (28,375)
Depreciation (115,325) (119,706)
Carrying amount, ending balance 1,301,080 465,868
Right-of-use Assets [Member] | At Cost [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance 593,339  
Carrying amount, ending balance 1,543,876 593,339
Right-of-use Assets [Member] | Accumulated Depreciation [Member]    
Reconciliation of changes in property, plant and equipment [abstract]    
Carrying value, beginning balance (127,471)  
Carrying amount, ending balance $ (242,796) $ (127,471)
v3.23.2
TRADE AND OTHER PAYABLES (Details) - USD ($)
Dec. 31, 2022
Jun. 30, 2022
Current [Abstract]    
Trade payables $ 357,937 $ 1,677,757
Accruals 395,508 196,450
Employee benefits 714,826 25,141
Total trade and other current payables $ 1,468,271 $ 1,899,348
v3.23.2
LOANS AND BORROWINGS (Details) - USD ($)
Dec. 31, 2022
Jun. 30, 2022
Current [Abstract]    
Lease liabilities $ 358,112 $ 128,653
Other loans and borrowings 5,748 5,594
Total current loans and borrowings 363,860 134,247
Non-current [Abstract]    
Lease liabilities 760,633 377,920
Other loans and borrowings 27,958 30,863
Total non-current loans and borrowings 788,591 408,783
Total loans and borrowings $ 1,152,451 $ 543,030
v3.23.2
CONTRIBUTED EQUITY, Issued Capital (Details) - USD ($)
Dec. 31, 2022
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Issued capital [abstract]        
171,225,492 ordinary shares (June 30, 2022: 140,288,491) $ 44,914,632 $ 29,782,268    
Contributed Equity [Member]        
Issued capital [abstract]        
171,225,492 ordinary shares (June 30, 2022: 140,288,491) $ 44,914,632 $ 29,782,268 $ 29,669,773 $ 10,255,369
Number of ordinary shares issued (in shares) 171,225,492 140,288,491    
v3.23.2
CONTRIBUTED EQUITY, Movements in Issued Capital (Details) - USD ($)
6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Movements in Issued Capital [Abstract]    
Opening balance $ 29,782,268  
Issue of shares - exercise of options 121,270 $ 2,146,737
Conversion of RSUs 0  
Share issue costs (992,340) (428,812)
Closing balance $ 44,914,632  
Contributed Equity [Member]    
Movements in Issued Capital [Abstract]    
Opening balance (in shares) 140,288,491  
Opening balance $ 29,782,268 10,255,369
Issue of shares - share placement 16,117,800 17,604,000
Issue of shares - exercise of options 194,205 2,239,216
Conversion of RSUs 167,487  
Share issue costs $ (1,347,128) (428,812)
Closing balance (in shares) 171,225,492  
Closing balance $ 44,914,632 $ 29,669,773
Contributed Equity [Member] | Ordinary Shares [Member]    
Movements in Issued Capital [Abstract]    
Opening balance (in shares) 140,288,491 105,105,787
Issue of shares - share placement (in shares) 30,000,000 20,000,000
Issue of shares - exercise of options (in shares) 737,000 14,382,704
Conversion of RSUs (in shares) 200,001  
Closing balance (in shares) 171,225,492 139,488,491
Contributed Equity [Member] | Class A [Member]    
Movements in Issued Capital [Abstract]    
Opening balance (in shares) 19,800,000 19,800,000
Issue of shares - share placement (in shares) 0 0
Issue of shares - exercise of options (in shares) 0 0
Conversion of RSUs (in shares) 0  
Closing balance (in shares) 19,800,000 19,800,000
Contributed Equity [Member] | Class B [Member]    
Movements in Issued Capital [Abstract]    
Opening balance (in shares) 19,800,000 19,800,000
Issue of shares - share placement (in shares) 0 0
Issue of shares - exercise of options (in shares) 0 0
Conversion of RSUs (in shares) 0  
Closing balance (in shares) 19,800,000 19,800,000
v3.23.2
RESERVES, Summary (Details) - USD ($)
Dec. 31, 2022
Jun. 30, 2022
RESERVES [Abstract]    
Share based payments reserve $ 14,666,453 $ 12,985,856
Foreign currency translation reserve (698,976) (596,331)
Total Reserve $ 13,967,477 $ 12,389,525
v3.23.2
RESERVES, Movements in Share-based Payments Reserve (Details) - USD ($)
6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Movements in share based payments reserve [Abstract]    
Opening balance, Share-based payments reserve $ 12,985,856  
Exercise of options (121,270) $ (2,146,737)
Conversion of RSUs 0  
Share-based payments expense 1,566,231 $ 4,764,135
Closing balance, share-based payments reserve $ 14,666,453  
Listed Options [Member]    
Number of Options [Abstract]    
Outstanding at beginning of period (in shares) 0 12,624,214
Grant of employee incentive securities (in shares) 0 0
Exercise of options (in shares) 0 (12,606,704)
Grant of options to advisor (in shares) 0  
Expiry of options (in shares)   (17,510)
Outstanding at end of period (in shares) 0 0
Unlisted Options [Member]    
Number of Options [Abstract]    
Outstanding at beginning of period (in shares) 23,824,000 25,800,000
Grant of employee incentive securities (in shares) 424,372 600,000
Exercise of options (in shares) (737,000) (1,776,000)
Grant of options to advisor (in shares) 1,000,000  
Expiry of options (in shares)   0
Outstanding at end of period (in shares) 24,511,372 24,624,000
Performance Rights [Member]    
Number of Performance Rights and Restricted Stock Units [Abstract]    
Opening balance (in shares) 27,620,000 16,325,000
Grant of employee incentive securities (in shares) 1,135,000 8,990,000
Conversion of RSUs (in shares) 0  
Closing balance (in shares) 28,755,000 25,315,000
Restricted Stock Units [Member]    
Number of Performance Rights and Restricted Stock Units [Abstract]    
Opening balance (in shares) 600,000 0
Grant of employee incentive securities (in shares) 424,372 600,000
Conversion of RSUs (in shares) (200,001)  
Closing balance (in shares) 824,371 600,000
Share Based Payments Reserve [Member]    
Movements in share based payments reserve [Abstract]    
Opening balance, Share-based payments reserve $ 12,985,856 $ 4,738,007
Grant of employee incentive securities 0 0
Exercise of options (72,935) (92,479)
Conversion of RSUs (167,487)  
Grant of options to advisor 354,788  
Expiration of options   0
Share-based payments expense 1,566,231 4,764,135
Closing balance, share-based payments reserve $ 14,666,453 $ 9,409,663
v3.23.2
SUBSIDIARIES (Details)
6 Months Ended 12 Months Ended
Dec. 31, 2022
Jun. 30, 2022
IperionX Inc. [Member]    
Subsidiaries [Abstract]    
Country of Incorporation USA  
Equity Interest 100.00% 100.00%
IperionX Critical Minerals LLC [Member]    
Subsidiaries [Abstract]    
Country of Incorporation USA  
Equity Interest 100.00% 100.00%
IperionX Technology, LLC [Member]    
Subsidiaries [Abstract]    
Country of Incorporation USA  
Equity Interest 100.00% 100.00%
Hyperion Metals (Australia) Pty Ltd [Member]    
Subsidiaries [Abstract]    
Country of Incorporation Australia  
Equity Interest 100.00% 100.00%
Calatos Pty Ltd, LLC [Member]    
Subsidiaries [Abstract]    
Country of Incorporation USA  
Equity Interest 100.00% 100.00%
v3.23.2
CONTINGENT ASSETS AND LIABILITIES (Details)
6 Months Ended
Dec. 31, 2022
USD ($)
a
Patent
Jul. 31, 2024
USD ($)
Jan. 31, 2024
USD ($)
Jul. 31, 2023
USD ($)
Jan. 31, 2023
USD ($)
Titan Project [Member]          
Contingent Assets and Liabilities [Abstract]          
Surface area of property allowed for lease or purchase (in acres) | a 11,071        
Blacksand [Member]          
Contingent Assets and Liabilities [Abstract]          
Additional amount to be paid upon exercise of option to purchase $ 6,000,000        
Percent of purchase price to be paid in shares 30.00%        
Amount of commitment to invest upon exercise of option to purchase $ 1,000,000        
Percent of cumulative net sales to be paid as royalty 0.50%        
Blacksand [Member] | Bottom of range [member]          
Contingent Assets and Liabilities [Abstract]          
Number of global patents owned | Patent 40        
Threshold of assets and properties for royalty payment $ 300,000,000        
Blacksand [Member] | Option Period One [Member]          
Contingent Assets and Liabilities [Abstract]          
Additional amount to be paid upon exercise of option to purchase         $ 1,500,000
Blacksand [Member] | Option Period Two [Member]          
Contingent Assets and Liabilities [Abstract]          
Additional amount to be paid upon exercise of option to purchase       $ 1,500,000  
Blacksand [Member] | Option Period Three [Member]          
Contingent Assets and Liabilities [Abstract]          
Additional amount to be paid upon exercise of option to purchase     $ 1,500,000    
Blacksand [Member] | Option Period Four [Member]          
Contingent Assets and Liabilities [Abstract]          
Additional amount to be paid upon exercise of option to purchase   $ 1,500,000      
v3.23.2
SUBSEQUENT EVENTS AFTER BALANCE DATE (Details) - Subsequent Events [Member]
Jan. 18, 2023
USD ($)
Phases
SUBSEQUENT EVENTS AFTER BALANCE DATE [Abstract]  
Number of contract award phases | Phases 4
Top of range [member]  
SUBSEQUENT EVENTS AFTER BALANCE DATE [Abstract]  
Contract awards | $ $ 500,000

IperionX (NASDAQ:IPX)
過去 株価チャート
から 4 2024 まで 5 2024 IperionXのチャートをもっと見るにはこちらをクリック
IperionX (NASDAQ:IPX)
過去 株価チャート
から 5 2023 まで 5 2024 IperionXのチャートをもっと見るにはこちらをクリック